Therapeutic DNA vaccination of vertically HIV-infected children

Report of the first pediatric randomised trial (PEDVAC)

Paolo Palma, Maria Luisa Romiti, Carla Montesano, Veronica Santilli, Nadia Mora, Angela Aquilani, Stefania Dispinseri, Hyppolite K. Tchidjou, Marco Montano, Lars E. Eriksson, Stefania Baldassari, Stefania Bernardi, Gabriella Scarlatti, Britta Wahren, Paolo Rossi

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Subjects: Twenty vertically HIV-infected children, 6-16 years of age, with stable viral load control and CD4+ values above 400 cells/mm3. Intervention: Ten subjects continued their ongoing antiretroviral treatment (ART, Group A) and 10 were immunized with a HIV-DNA vaccine in addition to their previous therapy (ART and vaccine, Group B). The genetic vaccine represented HIV-1 subtypes A, B and C, encoded Env, Rev, Gag and RT and had no additional adjuvant. Immunizations took place at weeks 0, 4 and 12, with a boosting dose at week 36. Monitoring was performed until week 60 and extended to week 96. Results: Safety data showed good tolerance of the vaccine. Adherence to ART remained high and persistent during the study and did not differ significantly between controls and vaccinees. Neither group experienced either virological failure or a decline of CD4+ counts from baseline. Higher HIV-specific cellular immune responses were noted transiently to Gag but not to other components of the vaccine. Lymphoproliferative responses to a virion antigen HIV-1 MN were higher in the vaccinees than in the controls (p = 0.047), whereas differences in reactivity to clade-specific Gag p24, RT or Env did not reach significance. Compared to baseline, the percentage of HIV-specific CD8+ lymphocytes releasing perforin in the Group B was higher after the vaccination schedule had been completed (p = 0.031). No increased CD8+ perforin levels were observed in control Group A. Conclusions: The present study demonstrates the feasibility, safety and moderate immunogenicity of genetic vaccination in vertically HIV-infected children, paving the way for amplified immunotherapeutic approaches in the pediatric population. Trial registration: clinicaltrialsregister.eu 2007-002359-18; 2007-002359-18/IT.

Original languageEnglish
Article numbere79957
JournalPLoS One
Volume8
Issue number11
DOIs
Publication statusPublished - Nov 28 2013

Fingerprint

Pediatrics
Perforin
Vaccination
Vaccines
vaccination
HIV
vaccines
therapeutics
DNA
Human immunodeficiency virus 1
HIV Antigens
Immunization
HIV-1
AIDS Vaccines
DNA Vaccines
Lymphocytes
Safety
Active Immunotherapy
Feasibility Studies
recombinant vaccines

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Therapeutic DNA vaccination of vertically HIV-infected children : Report of the first pediatric randomised trial (PEDVAC). / Palma, Paolo; Romiti, Maria Luisa; Montesano, Carla; Santilli, Veronica; Mora, Nadia; Aquilani, Angela; Dispinseri, Stefania; Tchidjou, Hyppolite K.; Montano, Marco; Eriksson, Lars E.; Baldassari, Stefania; Bernardi, Stefania; Scarlatti, Gabriella; Wahren, Britta; Rossi, Paolo.

In: PLoS One, Vol. 8, No. 11, e79957, 28.11.2013.

Research output: Contribution to journalArticle

Palma, Paolo ; Romiti, Maria Luisa ; Montesano, Carla ; Santilli, Veronica ; Mora, Nadia ; Aquilani, Angela ; Dispinseri, Stefania ; Tchidjou, Hyppolite K. ; Montano, Marco ; Eriksson, Lars E. ; Baldassari, Stefania ; Bernardi, Stefania ; Scarlatti, Gabriella ; Wahren, Britta ; Rossi, Paolo. / Therapeutic DNA vaccination of vertically HIV-infected children : Report of the first pediatric randomised trial (PEDVAC). In: PLoS One. 2013 ; Vol. 8, No. 11.
@article{daee1518153c4ec6b22525deb9accfe6,
title = "Therapeutic DNA vaccination of vertically HIV-infected children: Report of the first pediatric randomised trial (PEDVAC)",
abstract = "Subjects: Twenty vertically HIV-infected children, 6-16 years of age, with stable viral load control and CD4+ values above 400 cells/mm3. Intervention: Ten subjects continued their ongoing antiretroviral treatment (ART, Group A) and 10 were immunized with a HIV-DNA vaccine in addition to their previous therapy (ART and vaccine, Group B). The genetic vaccine represented HIV-1 subtypes A, B and C, encoded Env, Rev, Gag and RT and had no additional adjuvant. Immunizations took place at weeks 0, 4 and 12, with a boosting dose at week 36. Monitoring was performed until week 60 and extended to week 96. Results: Safety data showed good tolerance of the vaccine. Adherence to ART remained high and persistent during the study and did not differ significantly between controls and vaccinees. Neither group experienced either virological failure or a decline of CD4+ counts from baseline. Higher HIV-specific cellular immune responses were noted transiently to Gag but not to other components of the vaccine. Lymphoproliferative responses to a virion antigen HIV-1 MN were higher in the vaccinees than in the controls (p = 0.047), whereas differences in reactivity to clade-specific Gag p24, RT or Env did not reach significance. Compared to baseline, the percentage of HIV-specific CD8+ lymphocytes releasing perforin in the Group B was higher after the vaccination schedule had been completed (p = 0.031). No increased CD8+ perforin levels were observed in control Group A. Conclusions: The present study demonstrates the feasibility, safety and moderate immunogenicity of genetic vaccination in vertically HIV-infected children, paving the way for amplified immunotherapeutic approaches in the pediatric population. Trial registration: clinicaltrialsregister.eu 2007-002359-18; 2007-002359-18/IT.",
author = "Paolo Palma and Romiti, {Maria Luisa} and Carla Montesano and Veronica Santilli and Nadia Mora and Angela Aquilani and Stefania Dispinseri and Tchidjou, {Hyppolite K.} and Marco Montano and Eriksson, {Lars E.} and Stefania Baldassari and Stefania Bernardi and Gabriella Scarlatti and Britta Wahren and Paolo Rossi",
year = "2013",
month = "11",
day = "28",
doi = "10.1371/journal.pone.0079957",
language = "English",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "11",

}

TY - JOUR

T1 - Therapeutic DNA vaccination of vertically HIV-infected children

T2 - Report of the first pediatric randomised trial (PEDVAC)

AU - Palma, Paolo

AU - Romiti, Maria Luisa

AU - Montesano, Carla

AU - Santilli, Veronica

AU - Mora, Nadia

AU - Aquilani, Angela

AU - Dispinseri, Stefania

AU - Tchidjou, Hyppolite K.

AU - Montano, Marco

AU - Eriksson, Lars E.

AU - Baldassari, Stefania

AU - Bernardi, Stefania

AU - Scarlatti, Gabriella

AU - Wahren, Britta

AU - Rossi, Paolo

PY - 2013/11/28

Y1 - 2013/11/28

N2 - Subjects: Twenty vertically HIV-infected children, 6-16 years of age, with stable viral load control and CD4+ values above 400 cells/mm3. Intervention: Ten subjects continued their ongoing antiretroviral treatment (ART, Group A) and 10 were immunized with a HIV-DNA vaccine in addition to their previous therapy (ART and vaccine, Group B). The genetic vaccine represented HIV-1 subtypes A, B and C, encoded Env, Rev, Gag and RT and had no additional adjuvant. Immunizations took place at weeks 0, 4 and 12, with a boosting dose at week 36. Monitoring was performed until week 60 and extended to week 96. Results: Safety data showed good tolerance of the vaccine. Adherence to ART remained high and persistent during the study and did not differ significantly between controls and vaccinees. Neither group experienced either virological failure or a decline of CD4+ counts from baseline. Higher HIV-specific cellular immune responses were noted transiently to Gag but not to other components of the vaccine. Lymphoproliferative responses to a virion antigen HIV-1 MN were higher in the vaccinees than in the controls (p = 0.047), whereas differences in reactivity to clade-specific Gag p24, RT or Env did not reach significance. Compared to baseline, the percentage of HIV-specific CD8+ lymphocytes releasing perforin in the Group B was higher after the vaccination schedule had been completed (p = 0.031). No increased CD8+ perforin levels were observed in control Group A. Conclusions: The present study demonstrates the feasibility, safety and moderate immunogenicity of genetic vaccination in vertically HIV-infected children, paving the way for amplified immunotherapeutic approaches in the pediatric population. Trial registration: clinicaltrialsregister.eu 2007-002359-18; 2007-002359-18/IT.

AB - Subjects: Twenty vertically HIV-infected children, 6-16 years of age, with stable viral load control and CD4+ values above 400 cells/mm3. Intervention: Ten subjects continued their ongoing antiretroviral treatment (ART, Group A) and 10 were immunized with a HIV-DNA vaccine in addition to their previous therapy (ART and vaccine, Group B). The genetic vaccine represented HIV-1 subtypes A, B and C, encoded Env, Rev, Gag and RT and had no additional adjuvant. Immunizations took place at weeks 0, 4 and 12, with a boosting dose at week 36. Monitoring was performed until week 60 and extended to week 96. Results: Safety data showed good tolerance of the vaccine. Adherence to ART remained high and persistent during the study and did not differ significantly between controls and vaccinees. Neither group experienced either virological failure or a decline of CD4+ counts from baseline. Higher HIV-specific cellular immune responses were noted transiently to Gag but not to other components of the vaccine. Lymphoproliferative responses to a virion antigen HIV-1 MN were higher in the vaccinees than in the controls (p = 0.047), whereas differences in reactivity to clade-specific Gag p24, RT or Env did not reach significance. Compared to baseline, the percentage of HIV-specific CD8+ lymphocytes releasing perforin in the Group B was higher after the vaccination schedule had been completed (p = 0.031). No increased CD8+ perforin levels were observed in control Group A. Conclusions: The present study demonstrates the feasibility, safety and moderate immunogenicity of genetic vaccination in vertically HIV-infected children, paving the way for amplified immunotherapeutic approaches in the pediatric population. Trial registration: clinicaltrialsregister.eu 2007-002359-18; 2007-002359-18/IT.

UR - http://www.scopus.com/inward/record.url?scp=84896739263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896739263&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0079957

DO - 10.1371/journal.pone.0079957

M3 - Article

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 11

M1 - e79957

ER -